<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020951</url>
  </required_header>
  <id_info>
    <org_study_id>PEPN21EHR</org_study_id>
    <secondary_id>PCTC-N15</secondary_id>
    <nct_id>NCT05020951</nct_id>
  </id_info>
  <brief_title>Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE</brief_title>
  <official_title>Pilot Study to Enable Electronic Laboratory Data Transfer Into Medidata Rave</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An initial step toward more accurate and complete data acquisition for clinical trials, the&#xD;
      Pediatric Early Phase Clinical Trials Network (PEP-CTN) and Pediatric Brain Tumor Consortium&#xD;
      (PBTC) will assess the feasibility of electronic transfer of laboratory data from&#xD;
      participating institutions' local electronic health records to the Medidata/RAVE that is&#xD;
      housed within each consortium's Uniform Resource Locator (URL). This study will assess&#xD;
      efficiency, effectiveness, and scalability of the laboratory data extraction and transfer&#xD;
      processes. This study will identify factors in the process that impact consortium operations,&#xD;
      central protocol activation and implementation to the point of declaring the site data-ready.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECITVES&#xD;
&#xD;
      I. To test the feasibility of implementing automated laboratory data extraction and data&#xD;
      transfer tools at multiple sites within PEP-CTN and PBTC.&#xD;
&#xD;
      SECONDARY OBJECTIVES&#xD;
&#xD;
      I. To identify and evaluate discrepancies between laboratory data received through&#xD;
      retrospective automated laboratory data extraction and manual data ascertainment during the&#xD;
      original conduct of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test the feasibility of implementing automated laboratory data extraction and data transfer tools at multiple sites within PEP-CTN and PBTC.</measure>
    <time_frame>18 months</time_frame>
    <description>Thorough evaluation of the data extraction and transfer process from each participating site to the PBTC and PEP-CTN databases. Establish feasibility of the proposed process at each site as well as the operations cores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify and evaluate discrepancies between laboratory data received through retrospective automated laboratory data extraction and manual data ascertainment during the original conduct of the study.</measure>
    <time_frame>18 months</time_frame>
    <description>Laboratory results identified through automated extraction and transfer will be evaluated to determine if all laboratory results submitted as part of the therapeutic study can be identified.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Accurate and Complete Data Acquisition for Clinical Trials</condition>
  <arm_group>
    <arm_group_label>Laboratory Data</arm_group_label>
    <description>Electronic transfer of laboratory data from participating institutions' local electronic health records to the Medidata/RAVE</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medidata RAVE</intervention_name>
    <description>Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.</description>
    <arm_group_label>Laboratory Data</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Laboratory data from patients previously enrolled on a subset of PEP-CTN and PBTC trials.&#xD;
        Studies include ADVL1412, ADVL1312, ADVL1411, PBTC-042, PBTC-047 (Stratum 1), PBTC-050, and&#xD;
        PBTC-051.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient Data Inclusion Criteria: Specific patient clinical research data to be included in&#xD;
        this study for retrospective data capture and analysis will originate from the following&#xD;
        PEP-CTN and PBTC studies:&#xD;
&#xD;
          -  PEP-CTN: ADVL1412, ADVL1312, ADVL1411&#xD;
&#xD;
          -  PBTC: PBTC-042, PBTC-047 (Stratum 1), PBTC-050, PBTC-051 (Stratum 1)&#xD;
&#xD;
        Participating Site Inclusion Criteria: Data from above clinical studies at the following&#xD;
        institutions will be included in the initial pilot, with potential to expand to other sites&#xD;
        at which patients on these studies were treated.&#xD;
&#xD;
          -  Site Participation: Children's Healthcare of Atlanta - Scottish Rite and Egleston,&#xD;
             Children's Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, Seattle&#xD;
             Children's Hospital, St. Jude Children's Research Hospital, Texas Children's Hospital,&#xD;
             and University of California, San Francisco - Mission Bay&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara Miller, MD, MSCE</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Healthcare of Atlanta/Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara Miller, MD, MSCE</last_name>
    <phone>(404)-727-9268</phone>
    <email>tamara.miller@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kieuhoa Vo, MD MAS</last_name>
      <phone>415-476-3831</phone>
      <email>kieuhoa.vo@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Arun Rangaswami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Fangusaro, MD</last_name>
      <phone>404-727-5012</phone>
      <email>jfangus@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Cash, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobey MacDonald, MD</last_name>
      <phone>404-727-1447</phone>
      <email>tobey.macdonald@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Tobey MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Glade Bender, MD</last_name>
      <phone>212-639-6729</phone>
      <email>gladebej@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Forlenza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Laetsch, MD</last_name>
      <phone>214-771-6530</phone>
      <email>laetscht@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Balis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Furman, MD</last_name>
      <phone>901-595-2403</phone>
      <email>wayne.furman@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Wayne Furman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Baxter, MD</last_name>
      <phone>832-824-4681</phone>
      <email>pabaxter@texaschildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Murali Chintagumpala, MD</last_name>
      <phone>(832) 822-4266</phone>
      <email>mxchinta@texaschildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Baxter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navin Pinto, MD</last_name>
      <phone>206-987-5783</phone>
      <email>navin.pinto@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Leary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

